Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST040
MIFTS: 70

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastric Adenocarcinoma

About this section

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 15 17 71
Adenocarcinoma of Stomach 12 6
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 54

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3717
NCIt 49 C4004
SNOMED-CT 67 408647009
UMLS 71 C0278701
Sources

Summaries for Gastric Adenocarcinoma

About this section
Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric papillary adenocarcinoma and adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Iron and Iron isomaltoside 1000 have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Sources

Related Diseases for Gastric Adenocarcinoma

About this section

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 33.8 TP53 ERBB2
2 adenocarcinoma 33.2 TP53 SMAD4 RAF1 PTEN PIK3CA KRAS
3 gastric cancer 32.7 TP53 SMAD4 RAF1 PTEN PRDM16-DT PIK3CA
4 esophageal cancer 32.4 TP53 SMAD4 PTEN PIK3CA KRAS HRAS
5 signet ring cell adenocarcinoma 32.3 TP53 KRAS HRAS ERBB2 CTNNB1
6 gastric cardia adenocarcinoma 32.0 TP53 HOTAIR H19
7 familial adenomatous polyposis 32.0 TP53 SMAD4 KRAS HRAS CTNNB1
8 adenoma 31.9 TP53 SMAD4 PIK3CA KRAS GNAS CTNNB1
9 barrett esophagus 31.7 TP53 SMAD4 ERBB2 CTNNB1
10 intrahepatic cholangiocarcinoma 31.7 TP53 SMAD4 PTEN KRAS FGFR2 ERBB2
11 squamous cell carcinoma 31.7 TP53 SMAD4 PTEN PIK3CA NEAT1 HRAS
12 peutz-jeghers syndrome 31.6 TP53 SMAD4 PTEN GNAS CTNNB1
13 pancreatic ductal adenocarcinoma 31.6 TP53 SMAD4 PTEN KRAS HOTAIR H19
14 appendix adenocarcinoma 31.6 KRAS HRAS GNAS
15 ovary adenocarcinoma 31.6 TP53 SMAD4 PTEN PIK3CA KRAS HRAS
16 gastrointestinal stromal tumor 31.5 TP53 RAF1 PTEN KRAS KIT HOTAIR
17 mucinous adenocarcinoma 31.5 TP53 KRAS KIT ERBB2
18 papillary adenocarcinoma 31.4 TP53 KRAS HRAS ERBB2
19 kidney cancer 31.4 TP53 RAF1 PTEN PIK3CA HOTAIR H19
20 barrett's adenocarcinoma 31.4 TP53 KRAS ERBB2
21 lynch syndrome 31.3 TP53 SMAD4 PTEN PIK3CA KRAS HRAS
22 breast adenocarcinoma 31.3 TP53 PIK3CA KRAS H19 ERBB2
23 cowden syndrome 31.3 TP53 SMAD4 PTEN PIK3CA HRAS ERBB2
24 li-fraumeni syndrome 31.3 TP53 SMAD4 PTEN KRAS HRAS ERBB2
25 bile duct cancer 31.3 TP53 SMAD4 PTEN KRAS HRAS ERBB2
26 in situ carcinoma 31.3 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
27 breast ductal carcinoma 31.3 TP53 SMAD4 PTEN ERBB2 CTNNB1
28 colorectal adenoma 31.2 TP53 KRAS HRAS CTNNB1
29 cervical adenocarcinoma 31.2 TP53 PTEN KRAS ERBB2
30 rectum adenocarcinoma 31.2 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
31 colorectal adenocarcinoma 31.2 TP53 PTEN KRAS KIT HRAS ERBB2
32 keratosis 31.2 TP53 PIK3CA KIT HRAS CTNNB1
33 thymoma 31.2 TP53 PIK3CA KIT HRAS CTNNB1
34 exanthem 31.1 KRAS KIT HRAS ERBB2
35 chordoma 31.1 TP53 RAF1 PTEN CTNNB1
36 gallbladder adenocarcinoma 31.1 TP53 PIK3CA ERBB2
37 endocervical adenocarcinoma 31.0 TP53 PIK3CA ERBB2
38 lymphoma 31.0 TP53 RAF1 PIK3CA NRAS KIT FGFR1
39 glioma 31.0 TP53 PTEN PIK3CA NEAT1 HOTAIR H19
40 lipomatosis 31.0 PTEN PIK3CA KRAS FGFR1
41 neurofibroma 31.0 TP53 PTEN KIT
42 pseudomyxoma peritonei 31.0 TP53 KRAS CTNNB1
43 cervical cancer 31.0 TP53 SMAD4 PTEN PIK3CA NEAT1 HRAS
44 ulcerative colitis 31.0 SMAD4 PIK3CA H19 CTNNB1
45 cholangiocarcinoma 31.0 TP53 SMAD4 RAF1 PIK3CA NEAT1 KRAS
46 testicular germ cell tumor 31.0 TP53 PTEN KIT HRAS
47 pancreatic cancer 31.0 TP53 SMAD4 RAF1 PTEN PIK3CA NEAT1
48 small cell carcinoma 31.0 TP53 PTEN KRAS KIT
49 bladder cancer 31.0 TP53 PTEN PIK3CA NRAS KRAS HRAS
50 transitional cell carcinoma 30.9 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma
Sources

Symptoms & Phenotypes for Gastric Adenocarcinoma

About this section

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.98 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.98 HRAS KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.98 KRAS
4 Decreased viability GR00106-A-0 10.98 KRAS
5 Decreased viability GR00221-A-1 10.98 FGFR1 HRAS KRAS PIK3CA RAF1 KIT
6 Decreased viability GR00221-A-2 10.98 FGFR1 HRAS KRAS PIK3CA RAF1
7 Decreased viability GR00221-A-3 10.98 HRAS NRAS
8 Decreased viability GR00221-A-4 10.98 PIK3CA BRAF
9 Decreased viability GR00249-S 10.98 BRAF FGFR2
10 Decreased viability GR00301-A 10.98 KRAS RAF1 BRAF FGFR2 KIT
11 Decreased viability GR00342-S-1 10.98 FGFR2
12 Decreased viability GR00342-S-2 10.98 FGFR2
13 Decreased viability GR00342-S-3 10.98 FGFR2
14 Decreased viability GR00381-A-1 10.98 KRAS BRAF
15 Decreased viability GR00386-A-1 10.98 FGFR1
16 Decreased viability GR00402-S-2 10.98 PIK3CA RAF1
17 Decreased cell migration GR00055-A-1 9.98 MAP2K2
18 Decreased cell migration GR00055-A-3 9.98 BRAF HRAS PIK3CA
19 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.8 BRAF FGFR1 FGFR2 MAP2K2 RAF1
20 Decreased substrate adherent cell growth GR00193-A-1 9.8 KIT
21 Decreased substrate adherent cell growth GR00193-A-2 9.8 KIT
22 Decreased substrate adherent cell growth GR00193-A-3 9.8 BRAF
23 Decreased substrate adherent cell growth GR00193-A-4 9.8 BRAF FGFR1 KIT
24 Increased cell death in HCT116 cells GR00103-A-0 9.33 CTNNB1 PIK3CA RAF1
25 Reduced mammosphere formation GR00396-S 9.23 BRAF GNAS H19 HRAS KRAS NRAS
26 Decreased sensitivity to paclitaxel GR00112-A-0 9.07 PTEN
27 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
2 cardiovascular system MP:0005385 10.53 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
3 cellular MP:0005384 10.5 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
4 endocrine/exocrine gland MP:0005379 10.5 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
5 growth/size/body region MP:0005378 10.49 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
6 homeostasis/metabolism MP:0005376 10.47 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
7 craniofacial MP:0005382 10.46 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
8 integument MP:0010771 10.45 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
9 digestive/alimentary MP:0005381 10.42 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 HRAS
10 embryo MP:0005380 10.42 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 KIT
11 mortality/aging MP:0010768 10.41 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
12 immune system MP:0005387 10.37 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
13 hematopoietic system MP:0005397 10.35 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
14 neoplasm MP:0002006 10.35 BRAF CTNNB1 ERBB2 FGFR2 GNAS HRAS
15 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
16 muscle MP:0005369 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
17 nervous system MP:0003631 10.3 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
18 hearing/vestibular/ear MP:0005377 10.28 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
19 normal MP:0002873 10.28 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
20 liver/biliary system MP:0005370 10.26 BRAF CTNNB1 FGFR2 GNAS KIT KRAS
21 adipose tissue MP:0005375 10.18 BRAF FGFR2 GNAS MAP2K2 PIK3CA PTEN
22 no phenotypic analysis MP:0003012 10.17 CTNNB1 FGFR1 FGFR2 GNAS HRAS KIT
23 renal/urinary system MP:0005367 10.06 BRAF CTNNB1 FGFR1 FGFR2 GNAS HRAS
24 reproductive system MP:0005389 10 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 KIT
25 pigmentation MP:0001186 9.97 BRAF CTNNB1 FGFR2 KIT KRAS NRAS
26 respiratory system MP:0005388 9.9 BRAF CTNNB1 ERBB2 FGFR2 GNAS HRAS
27 skeleton MP:0005390 9.86 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
28 vision/eye MP:0005391 9.4 BRAF CTNNB1 FGFR1 FGFR2 KIT KRAS
Sources

Drugs & Therapeutics for Gastric Adenocarcinoma

About this section

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
2
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
11
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
16
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
17
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
18
Durvalumab Approved, Investigational Phase 4 1428935-60-7
19
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21 Anti-Bacterial Agents Phase 4
22 Anti-Infective Agents Phase 4
23 Antiprotozoal Agents Phase 4
24 Antiparasitic Agents Phase 4
25 Gastrointestinal Agents Phase 4
26 Alkylating Agents Phase 4
27 Antacids Phase 4
28 Proton Pump Inhibitors Phase 4
29 Anti-Ulcer Agents Phase 4
30 Antitubercular Agents Phase 4
31 Respiratory System Agents Phase 4
32 Citrate Phase 4
33 Expectorants Phase 4
34 diuretics Phase 4
35
Bismuth Phase 4 7440-69-9 16682734 105143
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Cytochrome P-450 CYP3A Inhibitors Phase 4
38 Antimetabolites Phase 4
39
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
40
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
41
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
42
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
43
Floxuridine Approved Phase 3 50-91-9 5790
44
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
45
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
46
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
47
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
48
leucovorin Approved Phase 3 58-05-9 6006 143
49
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
50
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 335)
# Name Status NCT ID Phase Drugs
1 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
2 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
3 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
4 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
5 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
6 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
7 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
8 Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability Completed NCT04132479 Phase 4 Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg;Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg
9 An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE) Recruiting NCT04078152 Phase 4 Durvalumab
10 A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach Terminated NCT00871273 Phase 4 capecitabine
11 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy Unknown status NCT02240524 Phase 3
12 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study Unknown status NCT02537171 Phase 3 apatinib
13 Phase III, Randomized, Multicenter, Controlled Evaluation of S‐1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1（SOX）
14 A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0) Unknown status NCT01283217 Phase 3 DS;SP
15 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Unknown status NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
16 A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
17 Phase III Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection Unknown status NCT01711242 Phase 3 Capecitabine;Oxaliplatin
18 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
19 A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
20 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT01170663 Phase 3 Placebo;Paclitaxel
21 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
22 Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study Completed NCT01646476 Phase 3
23 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
24 A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
25 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
26 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
27 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
28 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
29 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
30 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
31 Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
32 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
33 An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV) Completed NCT00020787 Phase 3 cisplatin;fluorouracil
34 Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
35 Phase III Study of the Effect of Radical Gastric Surgery Versus Conventional Surgery on Recurrence and Survival in Patients With Advanced Stage Gastric Cancer. Completed NCT00260884 Phase 3
36 Phase III, Randomized, Open-label Study of Adjuvant Chemotherapy Combined With Chemoradiotherapy Versus Adujvant Chemotherapy After Standard D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma Recruiting NCT03973008 Phase 3 Adjuvant Chemotherapy
37 A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With XELOX Chemotherapy Compared to Placebo in Combination With XELOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma Recruiting NCT03802591 Phase 3 CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
38 A Multi-center, Open-label, Randomized Controlled Study of Albumin-bound Paclitaxel Plus S-1 Versus Oxaliplatin Plus S-1 (SOX) as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma Recruiting NCT03801668 Phase 3 Albumin-bound Paclitaxel plus S-1;Oxaliplatin plus S-1
39 GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study. Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
40 An Randomized, Multicenter, Open-label, Phase III Trial Comparing Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients With Locally Advanced Gastric Adenocarcinoma Recruiting NCT01815853 Phase 3 Neoadjuvant Chemotherapy;Adjuvant Chemotherapy
41 Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine
42 A Phase III Trial of Preoperative or Postoperative Chemoradiation Therapy for Potentially Resectable Adenocarcinoma of Stomach Cancer Recruiting NCT03223740 Phase 3
43 Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
44 A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) Recruiting NCT02773524 Phase 3 Regorafenib
45 A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) Recruiting NCT04248452 Phase 3 Capecitabine;Fluorouracil;Leucovorin;Leucovorin Calcium;Oxaliplatin
46 A Randomized Phase III Study Comparing POF (Paclitaxel/Oxaliplatin/Leucovorin/5-FU) With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer Recruiting NCT03788226 Phase 3 POF;CAPOX/SOX/FOLFOX
47 Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection (CAPOGA): A Large Multicenter Phase III Randomized Controlled Trial Recruiting NCT03817268 Phase 3 Capecitabine monotherapy
48 A Multicenter Randomized Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
49 The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial Recruiting NCT02423278 Phase 2, Phase 3 S-1+Oxaliplatin
50 A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel，Oxaliplatin Combined With S-1(DOS) Versus Oxaliplatin Combined With S-1(SOX)in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study) Active, not recruiting NCT03691454 Phase 2, Phase 3 Docetaxel;Oxaliplatin

Search NIH Clinical Center for Gastric Adenocarcinoma

Sources

Genetic Tests for Gastric Adenocarcinoma

About this section
Sources

Anatomical Context for Gastric Adenocarcinoma

About this section

MalaCards organs/tissues related to Gastric Adenocarcinoma:

40
Lymph Node, Liver, Lung, Bone, Colon, T Cells, Endothelial
Sources

Publications for Gastric Adenocarcinoma

About this section

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 6909)
# Title Authors PMID Year
1
The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. 61 54
20377133 2010
2
CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. 61 54
19820687 2010
3
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. 61 54
19925030 2009
4
No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. 61 54
20057967 2009
5
AFP-producing hepatoid adenocarcinoma of the stomach: a case report. 61 54
20062620 2009
6
Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. 61 54
19695681 2009
7
Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3. 54 61
20032392 2009
8
Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. 54 61
19369967 2009
9
Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. 54 61
20082274 2009
10
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. 54 61
19639178 2009
11
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]. 61 54
20017300 2009
12
[Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]. 61 54
20095346 2009
13
Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. 54 61
19336448 2009
14
EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment. 61 54
19002606 2009
15
HIF-1alpha determines the metastatic potential of gastric cancer cells. 61 54
19223895 2009
16
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
17
Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. 61 54
19688069 2009
18
Importance of gastrin in the pathogenesis and treatment of gastric tumors. 61 54
19115463 2009
19
Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. 61 54
18807090 2008
20
[Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma]. 54 61
19544643 2008
21
[Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. 54 61
19205384 2008
22
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. 61 54
19061514 2008
23
Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. 61 54
18781152 2008
24
Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma. 54 61
19102422 2008
25
Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. 54 61
18570890 2008
26
Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. 54 61
18081943 2008
27
Induction of apoptosis by linoleic acid is associated with the modulation of Bcl-2 family and Fas/FasL system and activation of caspases in AGS human gastric adenocarcinoma cells. 61 54
18361731 2008
28
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]. 61 54
18683800 2008
29
Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo. 54 61
17933865 2008
30
Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. 61 54
18262050 2008
31
The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. 61 54
18095267 2008
32
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. 61 54
18715846 2008
33
Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. 54 61
18091326 2008
34
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. 54 61
18172256 2008
35
Expression of COX-2 in stomach carcinogenesis. 61 54
19107602 2008
36
Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. 54 61
17689858 2007
37
Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. 61 54
18025257 2007
38
Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. 54 61
17937769 2007
39
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. 54 61
17377791 2007
40
[Garlic oil inhibits cyclin E expression in gastric adenocarcinoma cells]. 54 61
17715037 2007
41
Effect of vasoactive intestinal peptide on gastric adenocarcinoma. 61 54
17559364 2007
42
Genetic and epigenetic analysis of the KLF4 gene in gastric cancer. 54 61
17614846 2007
43
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. 54 61
19034345 2007
44
Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. 54 61
17552003 2007
45
Prognostic significance of maspin expression in human gastric adenocarcinoma. 61 54
17591106 2007
46
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. 54 61
17230506 2007
47
[Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. 54 61
18172343 2007
48
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. 61 54
17003101 2007
49
Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. 54 61
17351800 2007
50
Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications. 61 54
17922051 2007
Sources

Variations for Gastric Adenocarcinoma

About this section

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 361) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
2 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
3 SMAD4 NM_005359.6(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
4 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
5 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
6 TP53 NM_001126112.2(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
7 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
8 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
9 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
10 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
11 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
12 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
13 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
14 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp)SNV Pathogenic 13272 rs79184941 10:123279677-123279677 10:121520163-121520163
15 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
16 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
17 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
18 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
19 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
20 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
21 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
22 RAF1 NM_001354689.3(RAF1):c.770C>T (p.Ser257Leu)SNV Pathogenic 13957 rs80338796 3:12645699-12645699 3:12604200-12604200
23 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
24 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
25 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg)SNV Pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
26 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 39648 rs121913237 1:115258747-115258747 1:114716126-114716126
27 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
28 NRAS NM_002524.5(NRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 40468 rs121913250 1:115258748-115258748 1:114716127-114716127
29 NRAS NM_002524.5(NRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 40469 rs121913250 1:115258748-115258748 1:114716127-114716127
30 NRAS NM_002524.5(NRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 40470 rs121913237 1:115258747-115258747 1:114716126-114716126
31 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
32 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
33 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
34 TP53 NM_001126112.2(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
35 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
36 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
37 TP53 NM_001126112.2(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
38 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 177778 rs121913250 1:115258748-115258748 1:114716127-114716127
39 TP53 NM_001126112.2(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
40 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
41 NRAS NM_002524.5(NRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 219097 rs121913237 1:115258747-115258747 1:114716126-114716126
42 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys)SNV Pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
43 TP53 NM_001126112.2(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
44 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
45 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
46 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
47 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
48 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
49 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys)SNV Pathogenic 376050 rs121913284 3:178921553-178921553 3:179203765-179203765
50 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291

Cosmic variations for Gastric Adenocarcinoma:

9 (show top 50) (show all 45057)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 12
2 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 12
3 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 12
4 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 12
5 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 12
6 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 12
7 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 12
8 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 12
9 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 12
10 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 12
11 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 12
12 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 12
13 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 12
14 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
15 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 12
16 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 12
17 COSM101978786 XPO1 stomach,NS,carcinoma,adenocarcinoma c.1249C>T p.R417C 2:61493050-61493050 12
18 COSM101977484 XPO1 stomach,NS,carcinoma,adenocarcinoma c.382G>A p.G128R 2:61502022-61502022 12
19 COSM101978758 XPO1 stomach,NS,carcinoma,adenocarcinoma c.781C>T p.R261* 2:61496986-61496986 12
20 COSM101978769 XPO1 stomach,NS,carcinoma,adenocarcinoma c.3154C>T p.R1052C 2:61478882-61478882 12
21 COSM91376043 WT1 stomach,NS,carcinoma,adenocarcinoma c.1399A>T p.K467* 11:32392005-32392005 12
22 COSM91380538 WT1 stomach,NS,carcinoma,adenocarcinoma c.326C>T p.A109V 11:32435020-32435020 12
23 COSM91376032 WT1 stomach,NS,carcinoma,adenocarcinoma c.1403C>T p.T468I 11:32392001-32392001 12
24 COSM91376050 WT1 stomach,NS,carcinoma,adenocarcinoma c.1392C>G p.D464E 11:32392012-32392012 12
25 COSM91376024 WT1 stomach,NS,carcinoma,adenocarcinoma c.1405C>T p.H469Y 11:32391999-32391999 12
26 COSM91376062 WT1 stomach,NS,carcinoma,adenocarcinoma c.1376A>T p.K459M 11:32392028-32392028 12
27 COSM91373352 WT1 stomach,NS,carcinoma,adenocarcinoma c.1165C>T p.R389C 11:32396341-32396341 12
28 COSM91376084 WT1 stomach,NS,carcinoma,adenocarcinoma c.1403C>G p.T468S 11:32392001-32392001 12
29 COSM91365177 WT1 stomach,NS,carcinoma,adenocarcinoma c.1073C>T p.T358M 11:32399973-32399973 12
30 COSM91365621 WT1 stomach,NS,carcinoma,adenocarcinoma c.1502G>A p.R501H 11:32389110-32389110 12
31 COSM91376004 WT1 stomach,NS,carcinoma,adenocarcinoma c.991G>A p.G331R 11:32416500-32416500 12
32 COSM101789719 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 7:141723249-141723249 12
33 COSM88718278 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 1:215728169-215728169 12
34 COSM88706690 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 1:215878834-215878834 12
35 COSM88730784 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 1:215728281-215728281 12
36 COSM88763597 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 1:216422197-216422197 12
37 COSM88760265 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 1:215728362-215728362 12
38 COSM127065236 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8:102285736-102285736 12
39 COSM127056711 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8:102285262-102285262 12
40 COSM85199244 U2AF1 stomach,NS,carcinoma,adenocarcinoma c.68A>G p.K23R 21:43104379-43104379 12
41 COSM140496615 TTN stomach,NS,carcinoma,adenocarcinoma c.72860T>C p.L24287P 2:178573272-178573272 12
42 COSM140712014 TTN stomach,NS,carcinoma,adenocarcinoma c.53507G>A p.R17836H 2:178607095-178607095 12
43 COSM140869246 TTN stomach,NS,carcinoma,adenocarcinoma c.75574G>C p.E25192Q 2:178570558-178570558 12
44 COSM140849450 TTN stomach,NS,carcinoma,adenocarcinoma c.76779T>A p.F25593L 2:178569353-178569353 12
45 COSM140492669 TTN stomach,NS,carcinoma,adenocarcinoma c.72534A>C p.Q24178H 2:178573598-178573598 12
46 COSM140722447 TTN stomach,NS,carcinoma,adenocarcinoma c.70474T>C p.C23492R 2:178575658-178575658 12
47 COSM140601461 TTN stomach,NS,carcinoma,adenocarcinoma c.63361G>T p.A21121S 2:178588046-178588046 12
48 COSM140872494 TTN stomach,NS,carcinoma,adenocarcinoma c.51827A>G p.Y17276C 2:178609483-178609483 12
49 COSM140457071 TTN stomach,NS,carcinoma,adenocarcinoma c.4049G>A p.R1350H 2:178779033-178779033 12
50 COSM140494721 TTN stomach,NS,carcinoma,adenocarcinoma c.102154C>T p.R34052W 2:178534461-178534461 12

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma
Sources

Expression for Gastric Adenocarcinoma

About this section
Search GEO for disease gene expression data for Gastric Adenocarcinoma.
Sources

Pathways for Gastric Adenocarcinoma

About this section

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.39 TP53 SMAD4 RAF1 PTEN PIK3CA NRAS
2
Innate Immune System 65
Show member pathways
 14.24 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
3
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 14.06 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
4
ERK Signaling 63
Show member pathways
 14.04 TP53 SMAD4 RAF1 PTEN NRAS MAP2K2
5
HIV Life Cycle 65
Show member pathways
 13.95 SMAD4 RAF1 PIK3CA NRAS MAP2K2 KRAS
6
GPCR Pathway 63
Show member pathways
 13.93 TP53 SMAD4 RAF1 NRAS MAP2K2 KRAS
7
PEDF Induced Signaling 63
Show member pathways
 13.92 TP53 SMAD4 RAF1 NRAS MAP2K2 KRAS
8
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.8 SMAD4 RAF1 NRAS MAP2K2 KRAS KIT
9
TGF-Beta Pathway 63
Show member pathways
 13.77 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K2
10
Developmental Biology 65
Show member pathways
 13.74 SMAD4 RAF1 PIK3CA NRAS MAP2K2 KRAS
11
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.7 TP53 RAF1 PTEN PIK3CA NRAS KRAS
12
Akt Signaling 63
Show member pathways
 13.66 TP53 RAF1 PTEN NRAS KRAS KIT
13
Integrin Pathway 63
Show member pathways
 13.64 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
14
Cytokine Signaling in Immune system 65
Show member pathways
 13.61 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
15
CREB Pathway 63
Show member pathways
 13.57 RAF1 PTEN NRAS MAP2K2 KRAS KIT
16
PAK Pathway 63
Show member pathways
 13.55 SMAD4 PTEN NRAS KRAS KIT HRAS
17
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.53 RAF1 NRAS MAP2K2 KRAS KIT HRAS
18
IL-2 Pathway 63
Show member pathways
 13.47 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
19
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.46 TP53 RAF1 PIK3CA NRAS KRAS HRAS
20
Parkinson disease 36
Show member pathways
 13.42 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
21
TNFR1 Pathway 63
Show member pathways
 13.33 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
22
Phospholipase-C Pathway 63
Show member pathways
 13.33 TP53 RAF1 PTEN NRAS MAP2K2 KRAS
23
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.32 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K2
24
p70S6K Signaling 63
Show member pathways
 13.31 RAF1 NRAS MAP2K2 KRAS KIT HRAS
25
GAB1 signalosome 65
Show member pathways
 13.3 TP53 PTEN PIK3CA KIT FGFR2 FGFR1
26
G-Beta Gamma Signaling 63
Show member pathways
 13.28 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
27
fMLP Pathway 63
Show member pathways
 13.25 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
28
Human cytomegalovirus infection 36
Show member pathways
 13.2 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
29
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.19 RAF1 PTEN NRAS MAP2K2 KRAS HRAS
30
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.17 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
31
Focal Adhesion 36 1
Show member pathways
 13.17 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
32
Aldosterone synthesis and secretion 36
Show member pathways
 13.16 RAF1 NRAS MAP2K2 KRAS KIT HRAS
33
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 13.14 RAF1 KIT GNAS FGFR2 FGFR1 ERBB2
34
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.13 RAF1 PTEN PIK3CA NRAS MAP2K2 KRAS
35
MAPK Erk Pathway 66
Show member pathways
 13.11 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
36
CCR5 Pathway in Macrophages 63
Show member pathways
 13.11 RAF1 PIK3CA NRAS KRAS HRAS GNAS
37
Development Angiotensin activation of ERK 22
Show member pathways
 13.11 RAF1 PIK3CA NRAS MAP2K2 KRAS KIT
38
TCR Signaling (Qiagen) 63
Show member pathways
 13.09 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
39
Beta-Adrenergic Signaling 63
Show member pathways
 13.07 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
40
Downstream signaling of activated FGFR2 65
Show member pathways
 13.05 PIK3CA NRAS KRAS HRAS FGFR2 FGFR1
41
MAPK signaling pathway 36 1
13.04 TP53 RAF1 NRAS MAP2K2 KRAS KIT
42
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 13.03 RAF1 PTEN PIK3CA MAP2K2 KRAS HRAS
43
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 13.01 TP53 PTEN PIK3CA NRAS KRAS KIT
44
Development HGF signaling pathway 22
Show member pathways
 13 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
45
Apoptosis Modulation and Signaling 1
Show member pathways
 12.97 TP53 RAF1 PIK3CA NRAS MAP2K2 KRAS
46
Relaxin signaling pathway 36
Show member pathways
 12.94 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
47
PI3K-Akt signaling pathway 36
Show member pathways
 12.94 TP53 RAF1 PTEN PIK3CA NRAS MAP2K2
48
G-AlphaQ Signaling 63
Show member pathways
 12.93 RAF1 NRAS MAP2K2 KRAS HRAS GNAS
49
4-1BB Pathway 63
Show member pathways
 12.93 TP53 RAF1 NRAS MAP2K2 KRAS HRAS
50
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.93 RAF1 PIK3CA NRAS MAP2K2 KRAS HRAS
Sources

GO Terms for Gastric Adenocarcinoma

About this section

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.07 RAF1 PTEN PIK3CA NRAS KRAS KIT
2 cytosol GO:0005829 9.97 TP53 SMAD4 RAF1 PTEN PIK3CA MAP2K2
3 receptor complex GO:0043235 9.62 KIT FGFR2 FGFR1 ERBB2
4 cytoplasm GO:0005737 9.5 TP53 SMAD4 RAF1 PTEN PIK3CA MAP2K2
5 cytoplasmic side of plasma membrane GO:0009898 9.13 PTEN MAP2K2 KIT

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 intracellular signal transduction GO:0035556 10.08 SMAD4 RAF1 KIT ERBB2 BRAF
2 phosphorylation GO:0016310 10.06 RAF1 PIK3CA MAP2K2 KIT FGFR2 FGFR1
3 negative regulation of cell proliferation GO:0008285 10.04 TP53 SMAD4 RAF1 PTEN HRAS CTNNB1
4 negative regulation of gene expression GO:0010629 10.03 TP53 MAP2K2 HRAS FGFR1 CTNNB1
5 protein phosphorylation GO:0006468 10.01 RAF1 PIK3CA MAP2K2 KIT FGFR2 FGFR1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 PTEN HRAS FGFR2 BRAF
7 heart development GO:0007507 9.98 TP53 RAF1 PTEN ERBB2 CTNNB1
8 positive regulation of protein phosphorylation GO:0001934 9.97 RAF1 KRAS HRAS ERBB2
9 protein autophosphorylation GO:0046777 9.97 KIT FGFR2 FGFR1 ERBB2
10 positive regulation of cell proliferation GO:0008284 9.97 PTEN KRAS KIT HRAS FGFR2 FGFR1
11 in utero embryonic development GO:0001701 9.96 TP53 SMAD4 FGFR2 FGFR1 CTNNB1